(NASDAQ: MBRX) Moleculin Biotech's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Moleculin Biotech's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast MBRX's revenue for 2026 to be $165,089,901, with the lowest MBRX revenue forecast at $165,089,901, and the highest MBRX revenue forecast at $165,089,901. On average, 1 Wall Street analysts forecast MBRX's revenue for 2027 to be $96,992,051, with the lowest MBRX revenue forecast at $96,992,051, and the highest MBRX revenue forecast at $96,992,051.
In 2028, MBRX is forecast to generate $201,126,747 in revenue, with the lowest revenue forecast at $201,126,747 and the highest revenue forecast at $201,126,747.